GLP-1/GIP RAs clinical guidance updated
Based on new evidence from clinical studies and to make recommendations clearer, clinical practice recommendations for patients taking GLP-1 RA and dual GLP-1/GIP RAs prior to anaesthesia or sedation have been updated.
Representatives from ANZCA, the Gastroenterological Society of Australia, the Australian Diabetes Society, and the National Association of Clinical Obesity Services and Australian and New Zealand Metabolic and the Obesity Surgery Society have developed the revised recommendations, which now include a decision-aid flowchart linked to explanatory statements.
They now also include a clear statement regarding the recommendation not to withhold these drugs prior to a procedure.
The revised document is available here. Please send any feedback or queries to [email protected]
You might also be interested in...
The following candidates have met the criteria for invitation to the final viva examination in May 2025.
ANZCA has called for the federal government and shadow government to consider and deliver on six priorities and calls for action as part of the 2025 federal election.
New this month: updated GLP-1 Agonist guideline; Propofol supply issues in NZ; Discontinuation of Bridion; RCH sepsis guidelines; webAIRS article in ANZCA Bulletin (Autumn ed.)